Clinical trials: Infections, Respiratory
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT01602874
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65…
- Trial name
- NCT05559476
- Testing
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Where
- 46 sites in United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV Immunization, Healthy Volunteer
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life
The purpose of this study was to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection…
- Trial name
- NCT05437510
- Testing
- Nirsevimab
- Where
- 240 sites in France, Germany and 1 more
- Volunteers
- 8,057 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Bordetella Pertussis, Whooping Cough
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
The resurgence of pertussis is associated with an evolutionary mechanism under the pressure of current acellular vaccines, with a possible impact on vaccine effectiveness and disease expression.
- Trial name
- PERT-SEVEREII (NCT05897879)
- Testing
- Nasopharyngeal swab, Blood samples
- Where
- 14 sites in France
- Volunteers
- 210 people
- Sponsor
- Institut Pasteur
Coronavirus, SARS-CoV-2 Infection
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05633446
- Testing
- PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations)
- Where
- 2 sites in Philippines
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
COVID-19
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19.
- Trial name
- NCT04362189
- Testing
- HB-adMSC
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hope Biosciences Research Foundation
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
- Trial name
- NCT01527110
- Testing
- Intravenous (IV) zanamivir
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Upper Resp Tract Infection
TEM-PCR™ Prospective Clinical Utility Study
This is a randomized, open-label, multi-center, prospective study to assess the clinical utility of the TEM-PCR Upper Respiratory Infection (URI) Panel in adult subjects age 65 and older presenting to the primary care clinic with…
- Trial name
- NCT04248361
- Testing
- TEM-PCR URI Panel, SOC/Empiric Diagnosis
- Where
- 4 sites in United States
- Volunteers
- 314 people
- Sponsor
- Diatherix Laboratories, LLC
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory…
- Trial name
- NCT06585241
- Testing
- mRNA-1273 Variant-containing Formulation
- Where
- 6 sites in United States
- Volunteers
- 1,144 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection
The main objectives of this study are to assess the safety, tolerability and immunogenicity of the candidate SARS-CoV-2 vaccine, COVIDITY, when administered using a needle-free ID or IM injection device.
- Trial name
- NCT05047445
- Testing
- COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection, COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection, COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants
- Where
- South Africa
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Scancell Ltd
SARS-CoV-2 Infection, Influenza A
Project STARFISH - PRJ0002679
This is a non-interventional study to perform the clinical performance evaluation of the Starfish Test using prospectively collected matched nasopharyngeal and nasal swab samples from the same donor.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Trial name
- STARFISH (NCT05727202)
- Testing
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Where
- 17 sites in United States
- Volunteers
- 1,909 people
- Sponsor
- Thermo Fisher Scientific, Inc
Influenza
Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine
The purpose of the study is to verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to World Health Organization (WHO)/European Union (EU) recommendation for the…
- Trial name
- NCT01063088
- Testing
- Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)
- Where
- 2 sites in Austria, Belgium
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Osteoarthritis, Rheumatoid Arthritis
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Upper Respiratory Tract Infection
- Trial name
- NCT05214677
- Testing
- DW1809, DW1809-1
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Influenza
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 18 years and over
- Trial name
- NCT00329966
- Testing
- Surface Antigen, Inactivated, Influenza (form.2006-07)
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Novartis
Covid19
Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]
The Prevent-COVID study is a prospective, multicenter, randomized, two-armed, placebo-controlled, double-blind, interventional study in which the efficacy and safety of ivermectin in COVID-19 post-exposure prophylaxis (PEP) is…
- Trial name
- NCT05060666
- Testing
- Ivermectin
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Infectopharm Arzneimittel GmbH
Influenza
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
To describe the safety findings from Days 0 to 44 following injection of the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule in accordance with the…
- Trial name
- NCT00836953
- Testing
- Influenza virus vaccine (Pediatric formulation)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid19
Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm
This study investigates the diagnostic performance of an AI algorithm in the detection of COVID-19 pneumonia on chest radiographs.
- Trial name
- NCT04561024
- Testing
- AI model
- Where
- Hong Kong
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ensemble Group Holdings, LLC
Respiratory Syncytial Virus Infections
A Study of XW001 in Healthy Adult Subjects
This is the first-in-human, single-center, randomized, double-blinded, placebocontrolled, single-dose and multiple-dose escalation Phase Ia study
- Trial name
- NCT05642403
- Testing
- XW001
- Where
- China
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.